Home > Introduction > Board Members

Board Members

Raj Thampuran.jpg

Prof Raj Thampuran
Managing Director

Prof Raj Thampuran is Managing Director of A*STAR and Chairman of the ETPL Board. He joined A*STAR in 2000 and has held various executive positions in the Electronics, Engineering and Chemicals clusters, Institute of High Performance Computing, and in planning and policy. Prof Raj has a PhD in Materials Science, and attended the Advanced Management Programme in INSEAD (Fontainebleau). He received the National Academic Award in 1998 and a Public Administration Medal (Bronze) in 2007.
Philip Lim.jpg

Philip Lim 
Chief Executive Officer

Philip  Lim  is  CEO  of  ETPL.  He  was  with  the  Ministry  of  Defence  (MINDEF)  as  Brigadier  General  and  Head  of  Joint  Logistics, overseeing  all  logistics  and  engineering  matters. Philip has an MBA from the National University of Singapore, a Master of Science from Cranfield Institute of Technology and attended  the  Harvard  Business  School’s  Programme  for Management  Development.  Philip  was  awarded  the Commendation  Medal  (Military)  in  1995  and  the  Public Administration Medal, Silver (Military) in 2004. 
Abel Ang.jpg

Abel Ang 
Group Chief Operating Officer
Accuron MedTech


Abel Ang is the Chief Operating Officer of Accuron, where he has overall responsibility for Accuron’s Medical Device activities.  He has previously served as Senior Advisor to the CEO of Greatbatch, providing commercialisation advice on medical device technologies into healthcare markets. Prior to Greatbatch, Abel was President, Asia Pacific for Hill-Rom and also served as its Chief Technology Officer. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board’s Biomedical Division.  He currently serves on the Board of Economic Development Innovations in Singapore, and the Boards of the following Accuron Medical Device Operating companies: Dornier Medizintechnik, Veredus Pte Ltd, Advanced Materials Technologies (AMT) Pte Ltd and Aslan Pharmaceuticals Ltd.
Carl Firth.jpg

Dr Carl Firth 
Founder & CEO
ASLAN Pharmaceuticals

Dr Carl Firth is CEO of ASLAN Pharmaceuticals, which develops novel medicines for global markets. He was previously Head of Asia Healthcare at Bank of America Merrill Lynch, and has more than five years of pharmaceutical R&D experience. Dr Firth has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence. He holds a PhD from Cambridge University in Molecular Biology and an Executive MBA from London Business School.
Jean-Luc Butel.jpeg

Mr Jean-Luc Butel

Global Healthcare Advisor and President, K8 Global Pte Ltd,

Senior Advisor, McKinsey & Co.

Prior to his appointment as Senior Advisor in McKinsey & Co. in July 2015, Jean-Luc Butel was President at Baxter Healthcare (Asia) Pte Ltd and was responsible for leading its international operations. He was also Global Healthcare Advisor and President of K8 Global Pte Ltd, and was previously Executive Vice President and Group President of International Operations at Medtronic Inc. overseeing Medtronic's operations outside of the United States. He was responsible for managing and driving all business activities for Medtronic in the Asia Pacific region. He has been Non-Executive and Independent Director at Biosensors International Group, Ltd. since March 2, 2015. He serves as a Director of Singapore Economic Development Board.
Kevin Wong.jpg

Mr Kevin Wong  
Bosons Capital Pte Ltd

Mr. Kevin Wong is the Chairman of Bosons Capital Pte Ltd. He was the Group CEO of Keppel Land Limited for 13 years. Keppel Land is one of the largest listed real estate companies in Singapore and has investments and developments in over 10 countries in Asia. Prior to joining Keppel Land, Mr Wong was with various companies in related industries in the US, UK, and Hong Kong. Mr Wong was the Chairman of Alpha Investment Partners Limited and Deputy Chairman of K-REIT Asia Management Limited, both are fund management companies with over S$8.5 billion and S$6.5 billion assets under management respectively.